Update on Potential Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis
Posted: Wednesday, May 12, 2021
According to Xiongbing Zu, PhD, MD, of Central South University, Changsha, China, and colleagues, most biomarkers for predicting bladder cancer lymph node metastasis seem to be related to the proliferation, migration, and invasion of tumor cells. The findings of their literature review were published in Frontiers in Oncology.
“MiR-143, miR-101, miR-133b, MALAT1, CXCL5, and VEGF-C are more likely to be prognostic factors for bladder cancer with lymph node metastasis, but a large number of retrospective studies are still needed for further verification.”
Most microRNAs (miRNA) inhibit the lymph node metastasis of bladder cancer, according to the investigators. Studies have shown that the expression levels of miR-101 and miR-133b were reduced in bladder tumors; these downregulations seemed to be significantly associated with lymph node metastasis. Another miRNA, miR-143, appeared to be downregulated in the serum of patients with lymph node metastasis.
Long noncoding RNAs (lncRNA) may act as oncogenes to promote lymphatic metastasis of bladder cancer. Specifically, the expression of MALAT1 seemed to be positively associated with lymph node metastasis; it also appeared to enhance the cisplatin resistance of bladder cancer cells.
The lymphangiogenesis factor VEGF-C seems to act as an oncogene; the expression levels of VEGF-C appeared to be significantly higher in patients with lymph node metastasis than in those without. The overexpression of CXCL5 may also promote disease progression; the levels of expression were higher in bladder cancer tissues than in normal tissues, which seemed to be associated with lymph node metastasis.
Disclosure: The study authors reported no conflicts of interest.